Investing.comCodex · 实盘不做把握 5/10不做原因:风险收益比不佳
北京时间·🕒 发布 21:04:34·⟳ 抓取 21:05:49 +1m15s·⚡ 决策 08-27 22:08:50 +1h03m·60.8 天前
雅培Amulet 360左心耳封堵器获CE Mark，拟在欧洲扩大供应
这是明确正面产品准入事件，但属于超大市值医疗器械公司的单品区域准入，未披露销售规模或财务指引增量，且美国仍未商业化；在缺少实时行情、内部案例库和可验证先例定价的情况下，不足以形成正期望交易。
📄 原文Investing.com↗ 原文
Abbott receives CE Mark for Amulet 360 stroke prevention device
Nvidia shares rise as strong AI demand powers bumper earnings, bullish outlook ABBOTT PARK, Ill. - Abbott (NYSE:ABT) an…
不做 雅培（ABT.US）
产品准入利好属实但未披露可量化收入或指引增量，雅培体量大且缺少实时行情与先例定价验证，风险收益不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
雅培Amulet 360获CE Mark并开始欧洲首批使用，证明产品准入和临床推进顺利；但雅培收入基数很大，该事件未披露订单、价格、装机或收入指引，短线增量难以相对集团市值形成足够弹性，因此选择不交易。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- Investing.com转述称雅培宣布Amulet 360获得CE Mark并将在欧洲扩大供应；本轮未打开到雅培官网原文，按转述处理。
- Investing.com发布AI辅助编辑审核新闻，扩散雅培Amulet 360获CE Mark事件。
关键理由
- CE Mark使Amulet 360具备欧洲商业化准入，欧洲首批手术完成说明上市推进已开始。
- VERITAS研究披露高植入成功率和较低早期并发症，有利于医生采用和产品迭代叙事。
主要风险
- 美国仍仅限研究性使用，欧洲准入尚未转化为可量化收入或指引上调。
- 雅培集团收入和市值基数很大，单一电生理器械区域准入的短线弹性可能不足。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-27 · 影响 weakens
未见报道披露订单金额、销售指引或对雅培集团收入的量化增量，削弱短线多头弹性。
检索:Abbott Amulet 360 CE Mark financial impact revenue guidance 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足使本次不能把产品准入利好升级为可执行多头，只保留基本面正向观察。
方向:医疗器械区域准入通常方向偏正面，但对超大市值公司需要订单、指引或收入量级才能支持短线交易。
涨幅量级:未能完成event_study，无法用高相似样本校准ABT.US的1至5日超额收益幅度。
形态:没有足够同市场、同机制、同相位样本判断是否存在见光死或高开低走模式。
原文全文
展开原文 · 2,070 字
Nvidia shares rise as strong AI demand powers bumper earnings, bullish outlook
ABBOTT PARK, Ill. - Abbott (NYSE:ABT) announced today it received CE Mark approval for its Amulet 360 Left Atrial Appendage Occluder, a device designed to reduce stroke risk in patients with non-valvular atrial fibrillation.
The device seals the left atrial appendage, a small pouch in the heart’s upper left chamber where blood clots commonly form in AFib patients. The implant offers an alternative for patients unable to take blood-thinning medication long-term.
Following approval, physicians completed the first European procedures using Amulet 360 at hospitals in Frankfurt and Lubeck, Germany, and Aarhus, Denmark. Abbott stated it will expand availability across European countries in coming weeks.
The device features a redesigned lobe that is softer and more conformable than Abbott’s previous-generation LAA occluder, with smaller anchors to secure it in place. An outer disk provides a second sealing layer.
The approval was supported by data from the VERITAS Study, which enrolled 400 patients at more than 30 hospitals across the U.S., Canada and Europe, according to the company’s press release statement. The study’s 45-day results, presented at the AF Symposium in Boston and published in JACC: Clinical Electrophysiology earlier this year, showed the device was successfully implanted in 99.8% of patients. The study reported no patient complications such as additional surgery, strokes, or blood clots within the first seven days after implantation. Complete closure of the LAA with zero leaks greater than 3 mm was achieved in 93.9% of patients by 45 days.
The CE Mark represents Abbott’s fourth major electrophysiology approval in just over a year, following U.S. and European approvals for the Volt PFA System in 2025 and European approval of TactiFlexâ„¢ Duo earlier this year.
The Amulet 360 device remains approved for investigational use only in the U.S.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ABBOTT PARK, Ill. - Abbott (NYSE:ABT) announced today it received CE Mark approval for its Amulet 360 Left Atrial Appendage Occluder, a device designed to reduce stroke risk in patients with non-valvular atrial fibrillation.
The device seals the left atrial appendage, a small pouch in the heart’s upper left chamber where blood clots commonly form in AFib patients. The implant offers an alternative for patients unable to take blood-thinning medication long-term.
Following approval, physicians completed the first European procedures using Amulet 360 at hospitals in Frankfurt and Lubeck, Germany, and Aarhus, Denmark. Abbott stated it will expand availability across European countries in coming weeks.
The device features a redesigned lobe that is softer and more conformable than Abbott’s previous-generation LAA occluder, with smaller anchors to secure it in place. An outer disk provides a second sealing layer.
The approval was supported by data from the VERITAS Study, which enrolled 400 patients at more than 30 hospitals across the U.S., Canada and Europe, according to the company’s press release statement. The study’s 45-day results, presented at the AF Symposium in Boston and published in JACC: Clinical Electrophysiology earlier this year, showed the device was successfully implanted in 99.8% of patients. The study reported no patient complications such as additional surgery, strokes, or blood clots within the first seven days after implantation. Complete closure of the LAA with zero leaks greater than 3 mm was achieved in 93.9% of patients by 45 days.
The CE Mark represents Abbott’s fourth major electrophysiology approval in just over a year, following U.S. and European approvals for the Volt PFA System in 2025 and European approval of TactiFlexâ„¢ Duo earlier this year.
The Amulet 360 device remains approved for investigational use only in the U.S.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。